Cargando…

Structure-Based Design of Novel Tetrahydro-Beta-Carboline Derivatives with a Hydrophilic Side Chain as Potential Phosphodiesterase Inhibitors

Tadalafil is a clinically approved phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction and pulmonary arterial hypertension. It contains two chiral carbons, and the marketed isomer is the 6R, 12aR isomer with a methyl substituent on the terminal nitrogen of the piperazinedione rin...

Descripción completa

Detalles Bibliográficos
Autores principales: Elhady, Ahmed K., Sigler, Sara C., Noureldin, Nazih, Canzoneri, Joshua C., Ahmed, Nermin S., Piazza, Gary A., Abadi, Ashraf H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5064235/
https://www.ncbi.nlm.nih.gov/pubmed/28117310
http://dx.doi.org/10.3390/scipharm84030428
_version_ 1782460114528108544
author Elhady, Ahmed K.
Sigler, Sara C.
Noureldin, Nazih
Canzoneri, Joshua C.
Ahmed, Nermin S.
Piazza, Gary A.
Abadi, Ashraf H.
author_facet Elhady, Ahmed K.
Sigler, Sara C.
Noureldin, Nazih
Canzoneri, Joshua C.
Ahmed, Nermin S.
Piazza, Gary A.
Abadi, Ashraf H.
author_sort Elhady, Ahmed K.
collection PubMed
description Tadalafil is a clinically approved phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction and pulmonary arterial hypertension. It contains two chiral carbons, and the marketed isomer is the 6R, 12aR isomer with a methyl substituent on the terminal nitrogen of the piperazinedione ring. In this report, tadalafil analogues with an extended hydrophilic side chain on the piperazine nitrogen were designed to interact with particular hydrophilic residues in the binding pocket. This leads to analogues with moderate inhibitory activity on phosphodiesterase-5, even for isomers in which chiral carbons are of the S configuration.
format Online
Article
Text
id pubmed-5064235
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-50642352016-10-27 Structure-Based Design of Novel Tetrahydro-Beta-Carboline Derivatives with a Hydrophilic Side Chain as Potential Phosphodiesterase Inhibitors Elhady, Ahmed K. Sigler, Sara C. Noureldin, Nazih Canzoneri, Joshua C. Ahmed, Nermin S. Piazza, Gary A. Abadi, Ashraf H. Sci Pharm Article Tadalafil is a clinically approved phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction and pulmonary arterial hypertension. It contains two chiral carbons, and the marketed isomer is the 6R, 12aR isomer with a methyl substituent on the terminal nitrogen of the piperazinedione ring. In this report, tadalafil analogues with an extended hydrophilic side chain on the piperazine nitrogen were designed to interact with particular hydrophilic residues in the binding pocket. This leads to analogues with moderate inhibitory activity on phosphodiesterase-5, even for isomers in which chiral carbons are of the S configuration. MDPI 2015-09-26 2016 /pmc/articles/PMC5064235/ /pubmed/28117310 http://dx.doi.org/10.3390/scipharm84030428 Text en © 2016 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Elhady, Ahmed K.
Sigler, Sara C.
Noureldin, Nazih
Canzoneri, Joshua C.
Ahmed, Nermin S.
Piazza, Gary A.
Abadi, Ashraf H.
Structure-Based Design of Novel Tetrahydro-Beta-Carboline Derivatives with a Hydrophilic Side Chain as Potential Phosphodiesterase Inhibitors
title Structure-Based Design of Novel Tetrahydro-Beta-Carboline Derivatives with a Hydrophilic Side Chain as Potential Phosphodiesterase Inhibitors
title_full Structure-Based Design of Novel Tetrahydro-Beta-Carboline Derivatives with a Hydrophilic Side Chain as Potential Phosphodiesterase Inhibitors
title_fullStr Structure-Based Design of Novel Tetrahydro-Beta-Carboline Derivatives with a Hydrophilic Side Chain as Potential Phosphodiesterase Inhibitors
title_full_unstemmed Structure-Based Design of Novel Tetrahydro-Beta-Carboline Derivatives with a Hydrophilic Side Chain as Potential Phosphodiesterase Inhibitors
title_short Structure-Based Design of Novel Tetrahydro-Beta-Carboline Derivatives with a Hydrophilic Side Chain as Potential Phosphodiesterase Inhibitors
title_sort structure-based design of novel tetrahydro-beta-carboline derivatives with a hydrophilic side chain as potential phosphodiesterase inhibitors
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5064235/
https://www.ncbi.nlm.nih.gov/pubmed/28117310
http://dx.doi.org/10.3390/scipharm84030428
work_keys_str_mv AT elhadyahmedk structurebaseddesignofnoveltetrahydrobetacarbolinederivativeswithahydrophilicsidechainaspotentialphosphodiesteraseinhibitors
AT siglersarac structurebaseddesignofnoveltetrahydrobetacarbolinederivativeswithahydrophilicsidechainaspotentialphosphodiesteraseinhibitors
AT noureldinnazih structurebaseddesignofnoveltetrahydrobetacarbolinederivativeswithahydrophilicsidechainaspotentialphosphodiesteraseinhibitors
AT canzonerijoshuac structurebaseddesignofnoveltetrahydrobetacarbolinederivativeswithahydrophilicsidechainaspotentialphosphodiesteraseinhibitors
AT ahmednermins structurebaseddesignofnoveltetrahydrobetacarbolinederivativeswithahydrophilicsidechainaspotentialphosphodiesteraseinhibitors
AT piazzagarya structurebaseddesignofnoveltetrahydrobetacarbolinederivativeswithahydrophilicsidechainaspotentialphosphodiesteraseinhibitors
AT abadiashrafh structurebaseddesignofnoveltetrahydrobetacarbolinederivativeswithahydrophilicsidechainaspotentialphosphodiesteraseinhibitors